The bidding window for TechDefence Labs SME IPO was open from September 15, 2025, to September 17, 2025. The basis of allotment will be finalised today, September 18, 2025. Here’s how you can check the IPO allotment status on the NSE and registrar’s website.
TechDefence Labs IPO is a book-building issue of ₹38.99 crores, consisting of a fresh issue of ₹0.20 crore shares. The price band is set between ₹183 and ₹193 per share. The tentative listing date on NSE Emerge is September 22, 2025.
GYR Capital Advisors Pvt. Ltd. is the book-running lead manager, and Purva Shareregistry (India) Private Limited is the registrar for the IPO.
Check out newly Listed IPOs on BSE and NSE.
The net proceeds from the fresh issue will be used to:
(September 17, 2025, end of the day)
Category |
Subscription (times) |
Qualified Institutional Investors (QIBs) |
284.17 |
Non-Institutional Investors (NIIs) |
1,279.03 |
Individual Investors (IND category bidding for 2 Lots) |
726.06 |
Total |
718.30 |
As of September 18, 2025, TechDefence Labs' IPO GMP stood at ₹195. The estimated listing price is expected to be ₹388 based on the upper price band of ₹193. The expected percentage gain per share is 101.04%.
Source: InvestorGain Report dated 18 September 2025 Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor we recommend or endorse trading in the grey market. |
TechDefence Labs offers cybersecurity solutions, including Managed Security Services, Cyber Program Managed Services, Vulnerability Assessment and Penetration Testing (VAPT), Compliance Services, Specialised Services and Staff Augmentation Services to enterprises.
Explore other Upcoming IPOs on BSE and NSE.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.